SDAI Limited Shareholders Unanimously Approve Diversification Into Biotechnology: Key Details From Extraordinary General Meeting
Summary of the Meeting
SDAI Limited convened its Extraordinary General Meeting (EGM) on 30 April 2026 at 6 Clementi Loop, Singapore. The meeting was attended by the Board of Directors, representatives from the company secretary office, the Sponsor (ZICO Capital Pte. Ltd.), scrutineers, a polling agent, and shareholders or their proxies.
Key Points From the EGM
- Main Resolution: The core agenda was the proposed diversification of SDAI Limited’s existing core business into the biotechnology sector.
- Voting Mechanism: All resolutions were conducted by poll in accordance with the Listing Manual Section B: Rule of Catalist of the Singapore Exchange.
- Shareholder Participation: Shareholders were invited to submit questions in advance, but none were received ahead of or during the meeting.
- Resolution Details: The resolution authorized the Company and its subsidiaries to invest in, acquire, or dispose of assets, businesses, or shares in entities within the biotechnology sector, and empowered the Directors to execute all necessary actions and documents to implement this diversification.
- Voting Outcome: The resolution was passed unanimously, with 100% of votes (119,346,060 shares) in favour and none against.
Important Information for Shareholders
- Strategic Shift: This approved diversification marks a significant and strategic shift in SDAI Limited’s business direction. The move into biotechnology could potentially open up new growth opportunities and revenue streams for the Group, and may significantly impact the company’s future financial performance.
- Authorisation and Flexibility: The resolution grants broad authorisation to the Board to pursue biotechnology ventures as they see appropriate, with flexibility to invest, purchase, acquire, or dispose of related assets and businesses, subject to compliance with Catalist Rules.
- Potential Impact on Share Value: As this represents a substantial diversification from the existing core business, it could have material implications for the company’s risk profile and future earnings. Investors should closely monitor subsequent announcements regarding specific investments or acquisitions in the biotechnology sector, as these could be price-sensitive events.
- No Shareholder Objections or Questions: The lack of questions and objections from shareholders may suggest a broad consensus or a high level of trust in the Board’s strategic direction.
Conclusion
The EGM was concluded at 2:45 p.m. with no other business discussed. With unanimous shareholder backing, SDAI Limited is now poised to pursue opportunities in biotechnology, potentially transforming its business landscape and value proposition.
Disclaimer
The information provided above is based on official company documentation and is intended for informational purposes only. Investors are advised to perform their own due diligence and consult professional advisors before making any investment decisions. This article does not constitute investment advice or a recommendation to buy or sell any securities.
盛大智能有限公司股东大会全票通过多元化进军生物科技业务——会议要点详细解读
会议摘要
盛大智能有限公司于2026年4月30日在新加坡金文泰环路6号召开了临时股东大会（EGM）。会议由董事会成员、公司秘书处代表、保荐人（ZICO Capital Pte. Ltd.）、监票人、计票代理以及股东和代理人出席。
会议核心要点
- 主要议题： 本次大会的核心议题为公司主营业务多元化，进军生物科技领域。
- 投票方式： 所有提案均以新交所Catalist板块相关规则进行投票表决。
- 股东参与： 公司事先邀请股东提交问题，但截止及会议期间均未收到相关提问。
- 决议内容： 董事会获授权可代表公司及其子公司投资、收购或处置与生物科技相关的资产、业务或股权，并可签署所有必要文件和采取相关行动以推进多元化战略。
- 投票结果： 决议获得全票通过，1.193亿股全部赞成，无反对票。
对股东的重要提示
- 战略转型： 此次通过的多元化决议标志着公司业务方向的重大调整，进军生物科技领域有望带来新的增长点与收入来源，对公司未来财务表现影响深远。
- 授权与灵活性： 董事会获得广泛授权，可灵活推进生物科技相关项目的投资、收购或处置，但需遵守Catalist相关规则。
- 对股价的潜在影响： 这一重大业务多元化可能改变公司风险结构与盈利前景，未来如有具体投资或并购公告，均可能成为影响股价的敏感事件。
- 无股东异议或提问： 股东未提出异议和疑问，或显示对董事会战略方向的高度信任与支持。
结论
会议于下午2:45顺利结束，未有其他事项讨论。在股东全票支持下，盛大智能将正式进军生物科技领域，或将迎来全新发展机遇与市场价值提升。
免责声明
以上内容基于公司官方文件，仅供参考。投资者应自行进行尽职调查并咨询专业顾问，本文不构成任何投资建议或买卖证券的推荐。
